Latest Research And Development News

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

Charger Metals secures $500,000 from Rio Tinto and advances a $1.1 million exploration program at Lake Johnston, boosting its cash position and drilling activity in Western Australia’s lithium hotspot.

Cann Group Limited has received a $315,552 advance on its expected FY2025 Research and Development Tax Incentive, marking the second tranche of funding to support its ongoing cannabis medicine development.

Adisyn Ltd has successfully completed a key R&D program on low-temperature graphene deposition, earning full approval and final payment of a $520,000 grant from the Israel Innovation Authority. This milestone validates its cutting-edge semiconductor technology aimed at revolutionizing AI and high-performance computing.

Enlitic, Inc. has launched a A$10 million placement alongside an offer of 125 million unquoted options, aiming to fuel growth in its AI-driven healthcare technology business. The move underscores both funding ambitions and the complex risks tied to AI adoption and market dynamics.

EVE Health Group has completed its acquisition of Nextract Pty Ltd, positioning itself to enter the lucrative erectile dysfunction and dysmenorrhea markets with innovative drug delivery technologies.

Lindian Resources has secured a combined $1.65 million cash inflow from the exercise of unlisted options and a government R&D tax refund, strengthening its financial position for advancing the Kangankunde Rare Earths Project.

Etherstack has landed a $1 million contract to supply digital radio network equipment to the world’s largest iron ore producer in Western Australia, reinforcing its growth in recurring revenues. The company also reports record cash receipts in the first half of 2025, signaling strong momentum.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

Synertec Corporation has signed a 12-month MOU with global battery leader Ritar International to integrate advanced OPzV battery technology into its Powerhouse microgrid system, aiming to slash costs and scale production rapidly.

Firebird Metals has installed new equipment at its Chinese R&D lab, enabling complete lab-scale production from ore to lithium manganese iron phosphate cathode. This milestone supports a strategic collaboration with Central South University and promises cost advantages in battery material manufacturing.